Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims Database
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
CONTEXT: Treatment Resistant Depression (TRD) is a significant and burdensome health concern. OBJECTIVE: To characterize, compare and understand the difference between TRD and non-TRD patients and episodes in respect of their episode duration, treatment patterns and healthcare resource utilization. DESIGN AND SETTING: Patients between 18 and 64 years with a new diagnosis of major depressive disorder (MDD) and without a previous or comorbid diagnosis of schizophrenia or bipolar disease were included from PharMetrics Integrated Database, a claims database of commercial insurers in the US. Episodes of these patients in which there were at least two distinct failed regimens involving antidepressants and antipsychotics were classified as TRD. PATIENTS: 82,742 MDD patients were included in the analysis; of these patients, 125,172 episodes were identified (47,654 of these were drug-treated episodes). MAIN OUTCOME MEASURES: Comparison between TRD and non-TRD episodes in terms of their duration, number and duration of lines of treatment, comorbidities, and medical resource utilization. RESULTS: Of the treated episodes, 6.6% (N = 3,134) met the criteria for TRD. The median time to an episode becoming TRD was approximately one year. The mean duration of a TRD episode was 1,004 days (vs. 452 days for a non-TRD episode). More than 75% of TRD episodes had at least four lines of therapy; half of the treatment regimens included a combination of drugs. Average hospitalization costs were higher for TRD than non-TRD episodes: $6,464 vs. $1,734, as were all other health care utilization costs. CONCLUSIONS: While this study was limited to relatively young and commercially covered patients, used a rigorous definition of TRD and did not analyze for cause or consequence, the results highlight high unmet medical need and burden of TRD on patients and health care resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 2×
“Consequently, there are a number of people with symptoms commonly associated with depression or diagnosed as suffering from MDD, who do not receive depression-related drug or other forms of treatment [24].”
BackgroundResultRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Depression and Type 2 Diabetes Over the Lifespan
Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008) · Diabetes Care · doi:10.2337/dc08-0985 · Cited by 1,558
The Relationship of Depression to Cardiovascular Disease: Epidemiology, Biology, and Treatment
Musselman, D. L., Evans, D. L., & Nemeroff, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.580 · Cited by 1,532
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280 · cited 1×
“In the US alone, the estimated direct and indirect cost amounted to $83 billion in 2000 [10], of which more than 50% of health expenditures were borne by the public sectors such as Medicaid, Medicare, state and local governments [11].”
BackgroundGaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1439 · Cited by 661
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386 · cited 2×
“Crown et al [17] included for comparison with TRD patients, such patients that were ‘‘diagnosed with depression who met initial antidepressant medication dosage selection criteria but did not meet criteria for treatment resistance’’.”
BackgroundResultEconomic implications of treatment-resistant depression among employees
Greenberg, P., Corey-Lisle, P. K., Birnbaum, H., Marynchenko, M., & Claxton, A. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422060-00003 · Cited by 113 · cited 2×
“Greenberg et al [26] have similarly shown higher incidence of comorbidities in TRD-likely employees as compared to MDD but TRD-unlikely employees in each of the 16 categories that they placed comorbidities in, e.”
BackgroundCorey-Lisle, P. K., Birnbaum, H. G., Greenberg, P. E., Marynchenko, M. B., & Claxton, A. J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0810 · Cited by 84
Research works printed but not linked: 8
- Hirschfeld RMA, Weissman MM (2002) Risk Factors For Major Depression And Bipolar Disorder. Neuropsychopharmacology: The Fifth Generation of Progress Section 8: Chapter 70.
- JI Ivanova, 2010, Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder, Curr Med Res Opin, 26, 2475, 10.1185/03007995.2010.517716 · DOI · Paper page
- MB Keller, 2005, Issues in treatment-resistant depression, J Clin Psychiatry, 66, 5
- E Vieta, 2011, Therapeutic options in treatment-resistant depression, Ann Med, 43, 512, 10.3109/07853890.2011.583675 · DOI · Paper page
- TB Gibson, 2010, Cost burden of treatment resistance in patients with depression, Am J Manag Care, 16, 370
- D Souery, 1999, Treatment resistant depression: methodological overview and operational criteria, Eur Neuropsychopharmacol, 9, 83, 10.1016/S0924-977X(98)00004-2 · DOI · Paper page
- CB Nemeroff, 2007, Prevalence and management of treatment-resistant depression, J Clin Psychiatry, 68, 17
- NS Philip, 2010, Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era, Expert Opin Pharmacother, 11, 709, 10.1517/14656561003614781 · DOI · Paper page
Cited by
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
“resistant depression may be marginally higher in women than in men (Kubitz et al. 2013).”
BackgroundZhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., & Sheehan, J. J. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13699 · Cited by 523
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Fonagy, P., Rost, F., Carlyle, J., McPherson, S., Thomas, R., Pasco Fearon, R. M., Goldberg, D., & Taylor, D. (2015) · World Psychiatry · doi:10.1002/wps.20267 · Cited by 237
“Treatments for major depressive disorder generally have medium effect sizes (3), but observational studies and trials consistently report high rates of non-response (4,5), with 12 to 20% of depressed patients not benefitting even from multiple courses of treatment (6).”
BackgroundFonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127
Self-citationDifficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
“…in a US database of 125,172 episodes of depression, it was reported that the duration of a treatment (in each level, from the 1st through the 10th) varied from 139 to 183 days, showing that patients too often receive the same insufficiently efficacious treatment for too long (Kubitz et al., 2013).”
BackgroundSackeim, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., Demitrack, M. A., George, M. S., Prudic, J., Thase, M. E., & Rush, A. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.021 · Cited by 109
The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review
Demyttenaere, K., & Van Duppen, Z. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy052 · Cited by 98
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden
Reutfors, J., Andersson, T. M.-L., Brenner, P., Brandt, L., DiBernardo, A., Li, G., Hägg, D., Wingård, L., & Bodén, R. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.030 · Cited by 94
Clinical research challenges posed by difficult-to-treat depression.
Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291721004943 · Cited by 89
“They are also high utilizers of mental and general health services in both outpatient and inpatient settings (Kubitz, Mehra, Potluri, Garg, & Cossrow, 2013; Olchanski et al., 2013), resulting in high health costs that often persist for years (Amos et al., 2018; Benson, Szukis, Sheehan, Alphs, &…”
Finding factors that predict treatment-resistant depression: results of a cohort study
Cepeda, M. S., Reps, J., & Ryan, P. (2018) · Depression and Anxiety · doi:10.1002/da.22774 · Cited by 80
Vieta, E., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.053 · Cited by 72
Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System
Sussman, M., O’sullivan, A. K., Shah, A., Olfson, M., & Menzin, J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.7.823 · Cited by 65
Saragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136343 · Cited by 63
McIntyre, R. S., Millson, B., & Power, G. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.045 · Cited by 60
Cepeda, M. S., Reps, J., Fife, D., Blacketer, C., Stang, P., & Ryan, P. (2018) · Depression and Anxiety · doi:10.1002/da.22705 · Cited by 50
Olfson, M., Amos, T. B., Benson, C., McRae, J., & Marcus, S. C. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.3.226 · Cited by 48
“Total health care costs, $ Total 17,997 (34,146) 10,325 (28,224) 6,749 (5,268-8,230) 5,923 (4,409-7,437) Mental health related 4,122 (8,657) 1,869 (6,643) 1,957 (1,586-2,327) 2,015 (1,607-2,423) Depression related 1,969 (4,203) 943 (3,314) 899 (725-1,072) 760 (595-925) Prescription pharmacy costs, $ Total 4,986 (9,529…”
Hershenberg, R., McDonald, W. M., Crowell, A., Riva-Posse, P., Craighead, W. E., Mayberg, H. S., & Dunlop, B. W. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.108 · Cited by 40
“Treatment-resistant depression (TRD) affects about one third of patients diagnosed with major depressive disorder (MDD), with a lifetime prevalence of approximately 1–5% of adults, depending on the definition of TRD used (Nemeroff, 2007; Kubitz et al., 2013).”
BackgroundThe economic cost of treatment-resistant depression in patients referred to a specialist service
McCrone, P., Rost, F., Koeser, L., Koutoufa, I., Stephanou, S., Knapp, M., Goldberg, D., Taylor, D., & Fonagy, P. (2018) · Journal of Mental Health · doi:10.1080/09638237.2017.1417562 · Cited by 33
Fife, D., Reps, J., Cepeda, M. S., Stang, P., Blacketer, M., & Singh, J. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00707 · Cited by 22
“Retrospective studies from health services databases, have often been used to describe the epidemiology and costs of TRD, but among such studies the proportion of PTD cases that develop into TRD cases ranges from 35% in a study limited to PTD subjects with a diagnosis of MDD [9] to less than 10% in a study that includ…”
BackgroundMethodEpidemiology of treatment resistant depression among major depressive disorder patients in Israel
Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04184-8 · Cited by 23
Rathod, S., Denee, T., Eva, J., Kerr, C., Jacobsen, N., Desai, M., Baldock, L., & Young, A. H. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.090 · Cited by 23
Lähteenvuo, M., Taipale, H., Tanskanen, A., Rannanpää, S., & Tiihonen, J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.010 · Cited by 20
Gillain, B., Degraeve, G., Dreesen, T., De Bruecker, G., Buntinx, E., Beke, D., Kestens, C., Valassopoulou, E., Verhelst, F., Peeters, E., et al. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00306-2 · Cited by 16
“Twentyfour percent of patients did not reach response to any therapy during the study period and remained in the MDE health state, confirming the reported unmet need for a subgroup of MDD patients who do not adequately respond to available therapies [7, 23, 25].”
MethodResultInfluentialJensen, K. J., Gronemann, F. H., Ankarfeldt, M. Z., Jimenez-Solem, E., Alulis, S., Riise, J., Bødker, N., Osler, M., & Petersen, J. (2022) · PLOS ONE · doi:10.1371/journal.pone.0275299 · Cited by 15
“It is a complex condition associated with comorbidities [7], higher risk of hospitalization and longer admission [8], increased suicidality and self-harm [9–11], increased risk of premature workforce exit [12], reduced quality of life, and poorer prognosis [13, 14] compared with nonTRD MDD patients.”
Background
Metadata
- Authors
- Kubitz, N., Mehra, M., Potluri, R. C., Garg, N., & Cossrow, N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-18
- Volume
- 8
- Issue
- 10
- Pages
- e76882
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2024075080
- Cited by
- 143
- References
- 10
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.